Credit Suisse Group Analysts Give Fresenius SE & Co KGaA (FRE) a €58.00 Price Target

Credit Suisse Group set a €58.00 ($67.44) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Friday. The firm currently has a neutral rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Sanford C. Bernstein set a €83.00 ($96.51) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Friday, September 21st. Warburg Research set a €80.00 ($93.02) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Friday, September 28th. Barclays set a €80.00 ($93.02) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Friday, September 28th. Commerzbank set a €79.00 ($91.86) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Friday, August 24th. Finally, Morgan Stanley set a €77.00 ($89.53) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Monday, September 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. Fresenius SE & Co KGaA currently has an average rating of Buy and a consensus price target of €68.69 ($79.88).

Shares of FRA FRE traded down €8.39 ($9.76) during mid-day trading on Friday, hitting €38.99 ($45.34). The company had a trading volume of 12,548,201 shares. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($69.95) and a 12 month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Google Finance Portfolio

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply